Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune cell therapy shows promise for aggressive blood cancer

NCT ID NCT04661020

Recruiting now Disease control Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Apr 10, 2026 · Last updated Apr 24, 2026 · Updated 3 times

Summary

This study tests a treatment called CD19 CAR-T therapy for people newly diagnosed with a fast-growing type of blood cancer called high-risk large B-cell lymphoma. The therapy uses a patient's own immune cells, which are modified in a lab to better find and attack cancer cells. The main goal is to see how many patients achieve complete remission (no cancer detected) three months after treatment. About 40 adults will take part in this phase 2 trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital，College of Medicine, Zhejiang University

    RECRUITING

    Hangzhou, Zhejiang, 310003, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LARGE B-CELL LYMPHOMA (LBCL)